Capsaicin alleviates cisplatin-induced muscle loss and atrophy in vitro and in vivo.

J Cachexia Sarcopenia Muscle

School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan.

Published: February 2023

Background: Cisplatin (CP) is a widely used chemotherapeutic drug with subsequent adverse effects on different organs and tissues including skeletal muscle loss and atrophy as the most common clinical symptoms. The molecular mechanism of cisplatin-induced muscle atrophy is not clearly understood. However, recent significant advances indicate that it is related to an imbalance in both the protein status and apoptosis. Capsaicin (CAP) is one of the major ingredients in chilli peppers. It is a valuable pharmacological agent with several therapeutic applications in controlling pain and inflammation with particular therapeutic potential in muscle atrophy. However, the mechanisms underlying its protective effects against cisplatin-induced muscle loss and atrophy remain largely unknown. This study aims to investigate capsaicin's beneficial effects on cisplatin-induced muscle loss and atrophy in vitro and in vivo.

Methods: The anti-muscle-atrophic effect of capsaicin on cisplatin-induced muscle loss was investigated using in vivo and in vitro studies. By using the pretreatment model, pretreated capsaicin for 24 h and treated with cisplatin for 48 h, we utilized a C C myotube formation model where cell viability analysis, immunofluorescence, and protein expression were measured to investigate the effect of capsaicin in hampering cisplatin-induced muscle atrophy. C57BL/6 mice were administered capsaicin (10, 40 mg/kg BW) as a pretreatment for 5 weeks and cisplatin (3 mg/kg BW) for seven consecutively days to assess muscle atrophy in an animal model for protein and oxidative stress examination, and the grip strength was tested to evaluate the muscle strength.

Results: Our study results indicated that cisplatin caused lower cell viability and showed a subset of hallmark signs typically recognized during atrophy, including severe reduction in the myotube diameter, repression of Akt, and mTOR protein expression. However, pretreatment with capsaicin could ameliorate cisplatin-induced muscle atrophy by up-regulating the protein synthesis in skeletal muscle as well as down-regulating the markers of protein degradation. Additionally, capsaicin was able to downregulate the protein expression of apoptosis-related markers, activated TRPV1 and autophagy progress modulation and the recovery of lysosome function. In vivo, capsaicin could relieve oxidative stress and cytokine secretion while modulating autophagy-related lysosome fusion, improving grip strength, and alleviating cisplatin-induced body weight loss and gastrocnemius atrophy.

Conclusions: These findings suggest that capsaicin can restore cisplatin-induced imbalance between protein synthesis and protein degradation pathways and it may have protective effects against cisplatin-induced muscle atrophy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891949PMC
http://dx.doi.org/10.1002/jcsm.13120DOI Listing

Publication Analysis

Top Keywords

cisplatin-induced muscle
32
muscle atrophy
24
muscle loss
20
loss atrophy
16
muscle
13
effects cisplatin-induced
12
protein expression
12
atrophy
11
cisplatin-induced
10
capsaicin
9

Similar Publications

Objective: Drug resistance and subsequent adverse effects, such as cancer cachexia, limit the clinical use of cisplatin. Oligonol® (Olg), a low-molecular-weight polyphenol, exhibits NF-κB inhibitory properties. NF-κB activation has been implicated in cisplatin resistance of cancer cells and skeletal muscle wasting.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on E2F transcription factor 8 (E2F8), highlighting its increased expression in bladder cancer tissues, which correlates with more advanced stages of the disease.
  • - Silencing E2F8 in bladder cancer cell lines leads to reduced cell proliferation and invasion, enhances apoptosis in response to cisplatin treatment, and affects the cell cycle by causing G1 phase arrest.
  • - E2F8 regulates the expression of MCM7, a factor involved in bladder cancer progression, and their interaction suggests that E2F8’s oncogenic effects may be mediated through MCM7.
View Article and Find Full Text PDF

Background: Cisplatin resistance is the leading cause of mortality in muscle-invasive bladder cancer (MIBC) cases. Previous evidence suggests that abnormal epitranscriptome modifications are associated with reduced chemotherapy responses. However, the exact underlying mechanism remains largely unknown.

View Article and Find Full Text PDF
Article Synopsis
  • The extracellular matrix (ECM) in skeletal muscle plays various roles beyond simply supporting muscle tissue, nerves, and blood vessels, but its specific functions are not well understood.
  • A study investigated how cisplatin, a chemotherapy drug, affects the expression of ECM-related genes during muscle atrophy in mice.
  • Results showed that cisplatin administration led to a decrease in the expression of several important ECM components, indicating a need for further research to understand the significance of these changes in muscle atrophy.
View Article and Find Full Text PDF
Article Synopsis
  • EW-7197 is a potent oral ALK5 inhibitor studied for its ability to reduce TGF-β1-induced fibrosis in both a 3D renal model and a mouse model.
  • In experiments, EW-7197 significantly lowered the expression of markers associated with fibrosis and reversed the effects of TGF-β, enhancing markers related to vascular growth and inflammatory responses.
  • Overall, the results suggest that EW-7197 could be effective in mitigating fibrotic processes in kidney disease, highlighting its potential as a therapeutic option.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!